Ryplazim Partnership dealThe wording of the PR has created confusion regarding the timing of the Ryplazim partnership deal. From previous corporate presentations the expectation had been created that it would occur before the refiling of the amended BLA not after approval by the FDA. The Jan 2020 corporate presentation also puts the partnership deal in advance of the refiling. Clearly the company has to clear the air on this matter.
Anticipated Key Milestones
1H-2020Expected commercial partnership for Ryplazim™
1H-2020Expected filing of amended BLA with FDA for Ryplazim™ (priority review expected